GBLX

GB Sciences, Inc. [GBLX] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

GBLX Stock Summary

Top 10 Correlated ETFs

GBLX

Top 10 Correlated Stocks

GBLX

In the News

GBLX Financial details

Company Rating
-
Market Cap
2.56M
Income
-6.03M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
3
Optionable
No
Shortable
Yes
Earnings
12 Feb 2024
P/E
-0.36
Forward P/E
-
PEG
0.01
P/S
-
P/B
-0.48
P/C
-
P/FCF
-2.02
Quick Ratio
0.02
Current Ratio
0.05
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.02
EPS next Y
-
EPS next Q
-
EPS this Y
-141470869.23%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
822.69%
Revenue last 5Y
-100%
Revenue Q/Q
-
EPS Q/Q
-54.55%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-2706%
ROE
165%
ROC
0.38%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.006-0.02
52W High
-
52W Low
-
RSI
37.18
Rel Volume
0.02
Avg Volume
125.6K
Volume
2.03K
Perf Week
0%
Perf Month
-88.89%
Perf Quarter
-92.48%
Perf Half Y
-93.15%
-
-
-
-
Beta
0.352
-
-
Volatility
0%, 0%
Prev Close
25%
Price
0.0005
Change
25%

Something similar

Top by Market Cap
GOOGL
AMZN
VTI
DHR-PB
META
Top Correlated ETFs
BTC.PA
DAPP.L
DAGB.L
GFOF.L
BCHS.L
Top Correlated Stocks
HFD.L
AEO.L
ARC.L
0L5A.L
BGO.L
Similar Market Cap
BRAXF
MDGS
BEDZ
PHSC.L
RVLP

Company Profile

Healthcare Biotechnology
  • Volume Average 125.6K
  • Market Capitalization 2.56M
  • Employee 3
  • CEO Mr. John Claybron Poss
  • Headquarters Las Vegas,NV,US
  • IPO Date 2008-05-12
  • Website https://www.gbsciences.com

GB Sciences, Inc. engages in the research and development of plant-based medicines in North America and Europe. The company offers cannabinoid-inspired medicines and complex therapeutic mixtures for the prescription drug market. Its intellectual property covers a range of conditions and programs in pre-clinical animal stage for Parkinson's disease, neuropathic pain, chronic pain, COVID-related cytokine release syndrome, depression/anxiety, and cardiovascular therapeutic programs. The company was formerly known as Growblox Sciences, Inc. and changed its name to GB Sciences, Inc. in October 2016. GB Sciences, Inc. was incorporated in 2001 and is based in Las Vegas, Nevada.